David L. Lucchino - CEO and Co-Founder
Christopher Loose, Ph.D. - CTO and Co-Founder
Laurence A. Roth - Product Development
Gregory Haas - Product Strategy and Regulatory
Ulla B. Wallin, RN - Clinical Affairs
Douglas Weaver - Manufacturing
David N. McClellan - Business Development
David L. Lucchino
Chief Executive Officer
Mr. Lucchino co-founded Semprus BioSciences in 2007. Under his stewardship, the company has grown from two to 30 employees and secured $28.5M in venture capital financing and $2.4M in federal funding. Prior to co-founding Semprus, Mr. Lucchino was a Senior Associate at Polaris Venture Partners, a $3B venture capital fund based in Boston. Mr. Lucchino was involved in the fund's investment in Athletes' Performance, a global leader for integrated performance training, nutrition and physical therapy. Previously, Mr. Lucchino co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in developing biomedical intellectual property. He led corporate development activities and secured funding for the firm's portfolio companies. LaunchCyte successfully co-founded six portfolio companies, including Knopp Neurosciences, which recently entered into an exclusive $345M license agreement with Biogen Idec, and Immunetrics, which entered into a joint development agreement through the purchase of a 29% stake by Royal Philips Electronics. He also led the firm's disruptive biomedical technologies assessment for Boston Scientific Corporation.
Mr. Lucchino is a Trustee of Mt. Auburn Hospital, a Harvard Medical School facility, where he serves on the hospital's Audit/Compliance and Nomination committees. He also serves on the Audit Committee for CareGroup: the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital. Additionally, Mr. Lucchino is a member of AdvaMed's (Advanced Medical Technology Association) Board of Directors, where he serves on the International Board Committee, as well as AdvaMed's 2012 Program Committee.
Mr. Lucchino began his career as a technology marketing executive. He earned an M.B.A. from Massachusetts Institute of Technology (MIT) Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University. He is a former member of the Board of Governors for the Sloan Fellows program and has served as a guest lecturer on entrepreneurship and innovation at MIT, Wharton Business School, Harvard Business School and Harvard Medical School.
Mr. Lucchino was honored by the Boston Business Journal as one of Boston's "40 under Forty" leading executives.
Outside the office, Mr. Lucchino is active with the National Outdoor Leadership School (NOLS), where he was part of an expedition that climbed Alaska's Mt. McKinley, North America's tallest mountain, and spent 95 days living in the Rocky Mountains as part of a leadership training program. He most recently rafted down Idaho's "River of No Return," the Salmon River, with NOLS.[ back to top ]
Christopher Loose, Ph.D.
Chief Technology Officer
Before co-founding Semprus BioSciences, Dr. Loose earned his Ph.D. in Chemical Engineering with Robert Langer and Gregory Stephanopoulos at the Massachusetts Institute of Technology. He received the Hertz Foundation Fellowship, awarded to fifteen of the top doctoral students in the U.S. across all applied sciences, and was selected as having the outstanding thesis among the Fellows. During his Ph.D. work, Dr. Loose developed a range of antimicrobial agents and materials for application to medical devices, as featured in Nature. He was also selected by Technology Review as a member of the TR35, representing 35 leaders under 35 years old most likely to impact the future of technology.
Prior to MIT, Dr. Loose was a Chemical Engineer at Merck Research Labs, executing pilot plant production of agents for clinical trials. His interest in material and active agent design began at Princeton University, where he graduated Summa Cum Laude, with a B.S.E in Chemical Engineering and developed a force field for predicting protein structure which has been used to redesign peptide agents currently in the clinic. Dr. Loose actively participates in a range of entrepreneurial events for students at Princeton, Harvard Business School, and MIT, encouraging promising technologists to enter the start- up world. Dr. Loose was recently honored by the Boston Business Journal as one of Boston's "40 under Forty" up and coming business leaders.[ back to top ]
Laurence A. Roth
Mr. Roth brings more than thirty years of medical device product development, clinical trial and operational experience to Semprus. Throughout his career, he has led the development and clinical evaluation of numerous products in the cardiology, surgery and biomaterials fields. Mr. Roth previously held executive roles at three venture-backed device companies in the Boston area - Arsenal Medical, Percardia and Focal, which went on to be purchased by Genzyme. At Percardia, Mr. Roth led development from concept through clinic trials for surgical and percutaneous cardiology products. At Focal, Mr. Roth assembled and led cross-disciplinary teams to identify new product opportunities, which led to collaborations with companies such as Roche, Novartis and Genzyme.
Mr. Roth began his career at C.R. Bard, where he held a variety of engineering and project management positions over 13 years working on innovative interventional products such as balloon catheters. He earned a B.S. and an M.E. in Biomedical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Babson College.
Product Strategy and Regulatory
Mr. Haas served as Vice President of Global Critical Care Research & Development at Arrow International, which was acquired by Teleflex in October 2007. In this role, Mr. Haas led a 50-person team that launched multiple new vascular access products. He had corporate responsibility for innovation strategy and design through product launch process optimization. Also at Arrow, Mr. Haas was Vice President of Product Development, Asia International, where his team utilized in-depth customer market research to develop devices designed specifically for targeted international markets.
He transitioned the early lab technology from research through the product development process to launch for the first and current market-leading short-term antimicrobial central venous catheter products. Mr. Haas holds an E.M. in Technology Management from the University of Pennsylvania, an M.S. in Biomedical Engineering from Drexel University, and a B.S. in Mechanical Engineering from the University of Pittsburgh.[ back to top ]
Ulla B. Wallin, RN
Prior to joining Semprus, Ms. Wallin served as International Clinical Project Director at NMT Medical, Inc., a Boston-based medical technology company. While at NMT, she oversaw and directed a number of post-market studies evaluating the efficacy of a Class III bio-absorbable structural heart implant. Ms. Wallin has also held leadership positions with BattelleCRO, Inc., of Newton, MA, where she provided in-depth senior project management oversight on full service clinical projects, and Dover, NH-based TissueLink Medical, Inc., where she planned, developed and implemented clinical feasibility and outcomes studies for 510(k) cleared, novel electrosurgical technology.
Ms. Wallin earned a B.S. in Nursing at Northeastern University and an M.S. in Health Policy Management from Harvard University's School of Public Health.[ back to top ]
Before joining Semprus in 2010, Mr. Weaver served for six years as Principal Engineer for Design Assurance and Supplier Compliance at Boston Scientific Corporation (BSC). Prior to joining BSC, Mr. Weaver held senior development posts at Genzyme Biosurgery, Inc., and Focal, Inc., the former synthetic surgical sealant manufacturer which was acquired by Genzyme. At Focal, Mr. Weaver was instrumental in leading the development of GMP compliant manufacturing processes while driving the scale-up and commercialization of the company's core polymer technology.
Mr. Weaver is a certified Six Sigma Green Belt and a HAZOPs Incident Commander. He holds an M.B.A. from National University, San Diego, CA, and earned a B.A. in Chemical Technology from Metropolitan State University, Minneapolis, MN.[ back to top ]
David N. McClellan
Prior to joining Semprus, Mr. McClellan served as President of Navilyst Medical, a Boston Scientific divestiture, which has product lines devoted to the Cardiovascular and Oncology markets. Mr. McClellan previously spent 21 years at Boston Scientific, where during his tenure as President of the Oncology business, he led several strategic acquisitions, pioneered multiple market leading technologies and developed clinician partnerships throughout the oncology community.
Mr. McClellan was a former board member of Beth Israel Deaconess Hospital-Needham and RFK Children's Action Corp. He is currently providing consulting services to medical technology companies and serving on boards of organizations dedicated to the healthcare industry, including privately held HealthSTAR Communications.[ back to top ]